LOGIN  |  REGISTER
Astria Therapeutics
Chimerix

Artivion to Participate in the 22nd Annual Needham Virtual Healthcare Conference

April 10, 2023 | Last Trade: US$43.74 0.29 -0.66

ATLANTA, April 10, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming 22nd Annual Needham Virtual Healthcare Conference. The Company's virtual fireside chat is scheduled to begin at 8:45 a.m. ET on April 18, 2023.  

A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page.  An archived copy of the webcast will be available for 90 days on the same website. 

About Artivion, Inc.

Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stents and stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.

Contacts:

  
   

Artivion

 

Gilmartin Group LLC       

D. Ashley Lee

 

Brian Johnston / Lynn Lewis

Executive Vice President and

 

Phone: 332-895-3222

Chief Financial Officer

 

This email address is being protected from spambots. You need JavaScript enabled to view it.

Phone: 770-419-3355

  

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page